REG - Haleon PLC - Haleon 2025 Half Year Results

HALEONAnnouncement

Thu 07:01

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250731:nRSe2714Ta&default-theme=true

RNS Number : 2714T  Haleon PLC  31 July 2025

 

 

Haleon plc: 2025 Half Year Results

 

31 July 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today
announces its half year results statement for the year ending 31 December 2025
is available at
http://www.rns-pdf.londonstockexchange.com/rns/2714T_1-2025-7-30.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/2714T_1-2025-7-30.pdf) .

 

The half year results statement will also be available on the Haleon website
www.haleon.com/investors (http://www.haleon.com/investors) , and the results
have been submitted in full unedited text to the Financial Conduct Authority's
National Storage Mechanism and will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

 

Dividend

Consistent with our policy to pay approximately one third of the prior year
full year dividend as the interim dividend the Board has declared a H1 2025
interim dividend of 2.2 pence per ordinary share, up 10% on the interim
dividend in 2024. This interim dividend is expected to be paid on 18 September
2025 to holders of ordinary shares and US American Depositary Shares (ADS) on
the register as of 15 August 2025 (the record date). The ex-dividend date is
expected to be 14 August 2025 for ordinary shareholders and 15 August 2025 for
holders of ADS. For ordinary shareholders wishing to participate in the
Dividend Reinvestment Programme (DRIP), the election deadline for the DRIP is
1 September 2025. The DRIP is provided by Equiniti Financial Services Limited,
more information is available at www.shareview.co.uk/info/drip
(http://www.shareview.co.uk/info/drip) .

 

Subject to market conditions and Board approval, Haleon expects to grow its
ordinary dividend at least in line with adjusted earnings.

 

Presentation for analysts and shareholders

A recorded results presentation by Brian McNamara, Chief Executive Officer,
and Dawn Allen, Chief Financial Officer, will be available shortly after
7:00am BST (8:00 am CEST) on 31 July 2025 and can be accessed at
www.haleon.com/investors (http://www.haleon.com/investors) . This will be
followed by a Q&A session at 9:30am BST (10:30am CEST).

For analysts and shareholders wishing to ask questions, please use the dial-in
details below which will have a Q&A facility:

 UK:         +44 (0) 808 189 0158
 US:         +1 855 979 6654
 All other:  +44 (0) 203 936 2999
 Passcode:   656863

An archived webcast of the presentation will be available later on the day of
the results and can be accessed at www.haleon.com/investors
(http://www.haleon.com/investors) .

This information contains regulated information as per 6.3.7R of the
Disclosure and Transparency Rules of the Financial Conduct Authority.

 

Amanda Mellor

Company Secretary

 

Enquiries

 Investors                                    Media

 Jo Russell              +44 7787 392441      Zoë Bird            +44 7736 746167
 Rakesh Patel            +44 7552 484646      Victoria Durman     +44 7894 505730

 Email: investor-relations@haleon.com         Email: corporate.media@haleon.com

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans six major categories - Oral Health, Vitamins, Minerals and Supplements
(VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin
Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin,
Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built
on trusted science, innovation and deep human understanding.

For more information please visit www.haleon.com (http://www.haleon.com) .

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IR RMMFTMTJJBLA